Schering Corporation

Novartis Ag

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Novartis Pharma Ag

Novartis Pharma Gmbh

Richard William Versace

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Patrick A Pinto

Kenneth Walter Bair

Frederick Ray Kinder, Jr

Stacy W Remiszewski

Lawrence Blas Perez

Michael Alan Green

Sushil Kumar Sharma

Lidia Cristina Sambucetti

Sompong Wattanasin

Christopher Turchik Jagoe

Anil K Saksena

Claudio Pisano

Loredana Vesci

Naginbhai M Patel

Margaret Ma Woo

Sara Zaknoen

Ronald Richard Linnartz

Gregory Burke

A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

Combinations of therapeutic agents for treating cancer

This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer 

Substituted lactams and their use as anti-cancer agents

The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

Deacetylase inhibitors

The present invention relates to certain substituted caprolactam carbonate and ether compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.

Use of certain substituted caprolactam carbonates and ethers in treating tumors

The present invention relates to certain substituted caprolactam compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.

Use of certain substituted caprolactams in treating tumors

Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors

The present invention relates to certain substituted caprolactam compounds of formula (I), where R,is (C,)alkyl or (C,)cycloalkyl; R,hydrogen or (C,)alkyl; X is (C,)alkynylene; (C,)alkynylene; m is 0 or 1; and R,is (C,)cycloalkyl; or an aromatic ring system selected from (II, III, IV and V), where R,is hydrogen, chloro, or methoxy; R,is hydrogen, chloro, (C,)alkyl or (C,)alkoxy, and Z is oxygen, sulfur, N&mdash;H, or N&mdash;CH,; or a pharmaceutically acceptable acid addition salt thereof, where possible, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.

Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation

The disclosed invention is compounds represented by the formula ##STR1## and pharmacetically acceptable acid salts thereof, wherein each Z is independently tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, lower alkoxy, phenoxy, nitrile, nitro, phenylsulfonyl, loweralkyl-sulfonyl, oxazol-2-yl, lower alkanoyl, benzoyl, lower alkoxycarbonyl, lower alkyl, lower alkylthio, phenyl, phenylaminothiocarbonyl, or lower alkylaminothiocarbonyl, hydroxyiminoloweralkyl hydroxyloweralkyl or carbonyl; or 4 or 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining member of the ring being at least one carbon, and optionally sulfur or oxygen, X and Y are each independently a bond, ##STR2## each Q is independently a divalent substituted or unsubstituted, straight or branched chain lower alkanediyl, lower alkanediyl-cycloalkanediyl-lower alkanediyl, lower alkenediyl, lower alkynediyl, phenylene, dihydrofurandiyl, loweralkanediyl-dihydrofurandiyl-loweralkanediyl, tetrahydrofurandiyl, tetrahydropyrandiyl, loweralkanediyl-tetrahydropyrandiyl-loweralkanediyl or, loweralkanediyl-tetrahydrofurandiyl-loweralkanediyl; W is a monovalent substituted or unsubstituted aryl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, with the proviso that W cannot be substituted or unsubstituted isoxazolyl, and with the further proviso that when Z is 2-chloro-4-methoxyphenyl, X is --O--, Q is C.sub.5 -C.sub.7 alkanediyl and Y is a bond, W is not imidazolyl substituted at positions 2, 4 and 5 with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyloweralkyl, nitro, loweralkoxycarbonyl, lower alkyl and amino methylene; W' is divale W. The compound is have antiviral activity, antiinflammatory activity and are PAF inhibitors.

Pharmaceutically active compounds

Orally active antiviral compounds

The invention relates to compounds of the formula ##STR1## wherein Z, X, Q, Y, W, and W' are as described herein. These compounds have antiviral activity, and certain of these compounds have antiinflammatory activity and are PAF inhibitors.

Certain substituted phenoxy-methyl phenyl-methoxy benzenes having

Growing community of inventors

Wanaque, NJ, United States of America

Richard William Versace